货号 | MAB463-500 |
描述 | For ELISA the Antibody Pairs information:Capture antibody:MAB463-500;Detection antibody:BAF463; and protein: 463-MG-025 |
别名 | CCF18; MIP-1 gamma |
反应种属 | Mouse |
应用 | Western Blot(1 µg/mL) ELISA Capture (Matched Antibody Pair)(2-8 µg/mL ) ELISA Detection (Matched Antibody Pair)(0.1-0.4 µg/mL ) ELISA Standard ( ) |
目标/特异性 | Detects mouse CCL9/10/MIP‑1 gamma in ELISAs and Western blots. In sandwich ELISAs, less than 0.02% cross-reactivity with recombinant human CCL3, 4, 15, 19, 20, recombinant mouse CCL3, 4, 19, or recombinant rat CCL20 is observed. |
使用方法 | Western Blot: 1 µg/mL ELISA Capture (Matched Antibody Pair): 2-8 µg/mL ELISA Detection (Matched Antibody Pair): 0.1-0.4 µg/mL ELISA Standard : Neutralization: Measured by its ability to neutralize CCL9/10/MIP‑1 gamma -induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR1. The Neutralization Dose (ND50) is typically 1-4 µg/mL in the presence of 0.04 µg/mL Recombinant Mouse CCL9/10/MIP‑1 gamma. |
来源 | Monoclonal Rat IgG1 Clone # 62105 |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 20308 (Mouse) |
应用文献 | |
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Response patterns of cytokines/chemokines in two murine strains after irradiation. | |
纯化方式 | Protein A or G purified from hybridoma culture supernatant |
免疫原 | E. coli-derived recombinant mouse CCL9/10/MIP‑1 gamma Gln22-Gln122 Accession # P51670 |
内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
生物活性 | Mouse |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
背景 | Mouse CCL9/10 (also named MIP-1 gamma and MRP-2) is an 11 kDa, secreted, monomeric polypeptide that belongs to the beta (or CC) intercrine family of chemokines (1‑3). Based on its activity and amino acid (aa) sequence, it is further classified as a member of the NC6 or six cysteine-containing CC subfamily of chemokines (2, 4, 5). This subfamily contains four N-terminally extended chemokines, two human (CCL15 and CCL23) and two mouse (CCL9 and CCL10). Within this subfamily, there are no human-to-rodent interspecies orthologs. Mouse CCL9/10 is synthesized as a 122 aa precursor that contains a 21 aa signal sequence and a 101 aa mature region with six cysteines. As noted, the mature region has an expanded N-terminus relative to other CC family members, and it forms a third intrachain disulfide bond with its two extra cysteines (3‑7). Mouse CCL9/10 is 75% aa identical to rat CCL9/10 (8). Chemokines are known to undergo proteolytic processing to generate multiple isoforms. NC6 chemokines are usually only marginally active at full‑length, but are converted to highly active forms upon N-terminal truncation. Mature CCL9, in the presence of inflammatory fluids, is naturally truncated by 28, 29 or 30 aa at the N-terminus, generating a highly active, 8 kDa, 71‑73 aa CCR1 ligand. In contrast, other CCR1 ligands, CCL3/MIP-1 alpha and CCL5/RANTES, lose their potency when proteolytically processed. CCL9/10 is constitutively secreted, and circulates as a full‑length molecule. Any onset of inflammation with subsequent enzyme release may act on local NC6 chemokines, generating early, potent leukocyte chemoattractants (5, 7). |
运输条件 | Blue Ice |
存放说明 | -20℃ |
参考文献 |
|
Chemotaxis Induced by CCL9/10/MIP‑1 gamma and Neutralization by Mouse CCL9/10/ MIP‑1 gamma Antibody. Recombinant Mouse CCL9/10/ MIP‑1 gamma (Catalog # 463-MG) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR1 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse CCL9/10/MIP‑1 gamma (0.04 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse CCL9/10/MIP‑1 gamma Monoclonal Antibody (Catalog # MAB463). The ND50 is typically 1-4 µg/mL. |